Piper Jaffray analyst JP McKim noted that Medtronic's (MDT) Guardian Connect system received FDA approval, but did not receive a non-adjunctive claim, which Dexcom (DXCM) and Abbott's (ABT) Libre have. The Guardian Connect system will not get Medicare coverage because of this, said McKim, who called the news a "nice win" for Dexcom in the near-term. While Kim does see Medtronic's system getting the claim eventually, he does not expect the Guardian Sensor to be a material threat to Dexcom in 2018 on a standalone basis, calling Medtronic a "pump first company." He keeps an Overweight rating on Dexcom shares.

Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.